trending Market Intelligence /marketintelligence/en/news-insights/trending/RacnD0686Fhg4xBLmBRUXA2 content esgSubNav
In This List

Syndax Pharmaceuticals plans $25M direct offering

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Syndax Pharmaceuticals plans $25M direct offering

Syndax Pharmaceuticals Inc. agreed to sell 2,021,018 shares to Biotechnology Value Fund LP and certain affiliates in a registered direct offering.

The company is expecting about $25 million in gross proceeds based on an offering price of $12.37 per share, which is the closing price of Syndax's shares on the Nasdaq Global Select Market on Oct. 13.

BTIG LLC served as a capital markets advisor to Syndax in connection with the offering.